Cutler Group LP Revance Therapeutics, Inc. Call Options Transaction History

Cutler Group LP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 07, 2023	SELL	$18.32 - $30.66 $355,408 - $594,804	-19,400 Reduced 80.83%	4,600 $1,000
Q3 2022 Oct 25, 2022	BUY	$14.33 - $28.47 $85,980 - $170,820	6,000 Added 33.33%	24,000 $110,000
Q2 2022 Aug 04, 2022	BUY	$11.52 - $20.4 $87,552 - $155,040	7,600 Added 73.08%	18,000 $22,000
Q1 2022 Apr 14, 2022	BUY	$12.36 - $20.31 $121,128 - $199,038	9,800 Added 1633.33%	10,400 $40,000
Q4 2021 Jan 18, 2022	BUY	$12.46 - $27.87 $7,476 - $16,722	600 New	600 $2,000
Q1 2021 Apr 26, 2021	SELL	$24.03 - $29.97 $36,045 - $44,955	-1,500 Closed	0 $0
Q4 2020 Jan 21, 2021	BUY	$23.41 - $28.34 $30,433 - $36,842	1,300 Added 650.0%	1,500 $1,000
Q3 2018 Nov 07, 2018	SELL	$23.55 - $30.1 $30,615 - $39,130	-1,300 Reduced 86.67%	200 $0
Q4 2017 Jan 17, 2018	BUY	$24.55 - $36.3 $2,455 - $3,629	100 Added 7.14%	1,500 $8,000
Q3 2017 Oct 17, 2017	BUY	$22.55 - $28.1 $31,570 - $39,340	1,400	1,400 $6,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.